Fundz

HepaRegeniX raises €15 million in Series C round led by Vesalius Biocapital IV for clinical development of HRX-215

PRIVATEJul 10, 2024

Amount Raised

€15 Million

Round Type

Series C

TübingenBiotechnologyHealth CareTherapeutics

Investors

Boehringer Ingelheim Venture FundHigh Tech GründerfondsNovo HoldingsVesalius Biocapital IV

Description

HepaRegeniX GmbH has announced the closing of a €15 million Series C round led by Vesalius Biocapital IV. The funds will be used to advance the clinical development of HRX-215, including a Phase Ib clinical trial in the US and an international multicenter Phase IIa clinical trial in liver regeneration. Elias Papatheodorou moves from Chair of the Board to CEO, and Dr. Linda Greenbaum joins as CMO.

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as HepaRegeniX GmbH that raised within 45 days of this round, from Fundz verified event records.

  • Navigator Medicines raised $50M on August 23, 2024.
  • Borealis Biosciences raised $150M (Series A) on August 22, 2024.
  • Retension Pharmaceuticals raised $10M (Series A) on August 21, 2024.
  • Pathalys Pharma raised $105M (Series B) on August 21, 2024.
  • Candid Therapeutics raised $206M on August 19, 2024.
  • IDRx raised $120M (Series B) on August 7, 2024.

Who to call at HepaRegeniX GmbH, and when

A new round usually means HepaRegeniX GmbH is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day HepaRegeniX GmbH raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at HepaRegeniX GmbH, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at HepaRegeniX GmbH. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

HepaRegeniX GmbH

Location

Tübingen, Baden-Württemberg, Germany

About

HepaRegeniX GmbH is a clinical-stage biotechnology company developing novel therapies for the treatment of acute and chronic liver diseases.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment HepaRegeniX GmbH raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for HepaRegeniX GmbH's next move

See what Strategic adds

HepaRegeniX GmbH raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.